# Moguisteine

MedChemExpress

Cat. No.:	HY-B0505				
CAS No.:	119637-67-1				
Molecular Formula:	C <sub>16</sub> H <sub>21</sub> NO <sub>5</sub> S				
Molecular Weight:	339.41				
Target:	Others				
Pathway:	Others				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	2 years		
		-20°C	1 year		

### **SOLVENT & SOLUBILITY**

In Vitro	DMSO : 100 mg/mL (294.63 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	2.9463 mL	14.7314 mL	29.4629 mL		
		5 mM	0.5893 mL	2.9463 mL	5.8926 mL		
		10 mM	0.2946 mL	1.4731 mL	2.9463 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution						

## **BIOLOGICAL ACTIVITY**

#### Description

Moguisteine(BBR-2173) is a novel peripheral non-narcotic antitussive drug.Target: OthersMoguisteine is a novel peripheral nonnarcotic antitussive agent that has proved to be as active as codeine in several experimental models of induced cough in guinea-pigs and dogs. It acts neither through the opiate receptors nor on the cough centre, and its action is possibly mediated by the interaction with rapidly adapting irritant receptors along the tracheobronchial tree. In controlled clinical trials, moguisteine has been shown to be safe and to effectively reduce cough associated with such respiratory disorders as acute upper respiratory tract infection, chronic bronchitis, pulmonary fibrosis and malignancies [1, 2].

# Product Data Sheet

Ö

## CUSTOMER VALIDATION

• EMBO Rep. 2022 Apr 11;e53932.

See more customer validations on <u>www.MedChemExpress.com</u>

### REFERENCES

[1]. Gallico, L., et al., Moguisteine: a novel peripheral non-narcotic antitussive drug. Br J Pharmacol, 1994. 112(3): p. 795-800.

[2]. Gallico, L., et al., Effects of moguisteine, a peripheral nonnarcotic antitussive agent, on airway inflammation in guinea-pigs in vivo. Eur Respir J, 1996. 9(3): p. 478-85.

#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA